The EMEA has recommended the European Commission approve Zeltia's drug Yondelis for the treatment of soft tissue sarcomas. The company's shares surged on the news. The recommendation comes almost four years after the EMEA rejected Zeltia's earlier submission. The company plans to begin selling the drug later this year. Report